Proscia®, a leading provider of AI-enabled digital pathology solutions, has made available the Concentriq Dx® digital pathology software for use in reviewing and reporting of digital pathology slides in the United States. Concentriq Dx, which is CE-marked for use in primary diagnosis in Europe, will support the need for remote pathology in the United States brought about by the COVID-19 pandemic. This announcement comes as the FDA has issued new guidance aimed at expanding the availability of remote digital pathology devices.
The current practice of pathology tethers pathologists to microscopes in physical laboratory spaces. By limiting access to these laboratories, the COVID-19 pandemic has crippled pathology operations, disrupting the ability to serve patients. This has created urgency around the adoption of digital pathology, which enables remote case review, to provide timely diagnosis. Recognizing this urgency, the FDA has introduced guidance on a policy to help expand the availability of remote digital pathology devices in an effort to facilitate pathology services while reducing healthcare personnel contact and risk of exposure to COVID-19.
Concentriq Dx enables pathologists to securely read cases from remote locations, including home offices, using an Internet browser. The software can be rapidly deployed on existing IT infrastructure and works with any scanner and laboratory information system (LIS), offering seamless integrations with Leica, 3DHISTECH, and Hamamatsu among other leading solutions.
Proscia is committed to helping pathologists practice uninterrupted during the COVID-19 pandemic through the use of digital pathology. This new availability of Concentriq Dx expands upon the company’s COVID Response Program to ensure that laboratories can get up-and-running quickly with digital pathology to maintain operations and continue to serve patients.
To learn more about how digital pathology is transforming the practice of pathology, please join Proscia for a webinar, “Streamlined Operations, Increased Revenue, Higher Quality of Care: Conclusive Evidence on the Value of Adopting Digital Pathology in Your Lab,” hosted by Dark Daily on May 13th at 1PM EDT.
Proscia is an AI software company that is changing the way the world practices pathology to transform cancer research and diagnosis. With the company’s Concentriq digital pathology platform and pipeline of AI algorithms, laboratories are leveraging new kinds of data to improve patient outcomes and accelerate discoveries. Proscia’s team of technologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision care. For more information, visit proscia.com.